Abstract:There has been little recent success in identifying novel analgesic drug targets and discovering better therapeutics for treating neuropathic pain. Existing analgesic drugs have significant safety, efficacy, tolerability and addiction concerns limiting their use. Recent studies have identified a critical ligand‐gated ion channel on peripheral sensory nerve fiber endings, transient receptor potential ankyrin 1 (TRPA1), as a promising novel analgesic target for treating neuropathic pain. TRPA1 is a validated analgesic target based upon TRPA1 knockout studies in established pain models, pharmacological studies with TRPA1 antagonists and human medical genetic data. Peripherally acting TRPA1 antagonists may provide a novel, safer and more effective option for treating neuropathic pain than existing analgesics. Utilizing a rational drug discovery approach, we have discovered a novel structural class of small molecule, reversible TRPA1 antagonists with excellent drug‐like features using a human TRPA1 fluorescence‐based intracellular calcium assay. Five potent antagonists, ALGX‐2513, ALGX‐2541, ALGX‐2563, ALGX‐2561 and ALGX‐2542, inhibited FFA agonist‐mediated responses with IC 50 s ranging from 23–65nM and were found to be highly selective (>100X) in assays for numerous related TRP channels. ALGX‐2437 and ALGX‐2513 inhibited AITC‐mediated TRPA1 calcium responses in isolated mouse dorsal root ganglion (DRG) neurons, confirming target engagement. In rat PK studies, dosing of ALGX‐2437 and ALGX‐2460 (30 mg/kg) produced robust in vivo drug exposure, achieving high C max values (5–10X IC 50 ) with t max values of 2 hr and t 1/2 values between 3–5 hrs. The analgesic effects of compounds in this series were evaluated in the spinal nerve ligation model (SNL) of neuropathic pain. A single dose (10–50mg/kg) of ALGX‐2437 showed dose‐dependent reversal (EC 50 = 25mg/kg) of mechanical hyperalgesia in the SNL pain model with a maximal possible efficacy (%MPE) of 79% at 2 hr post‐dosing (p<0.0001). Analysis of brain and blood levels showed low brain penetrance of the drug at all dose levels. No adverse behavioral effects, including impairment of rotarod performance, were observed at all doses. In addition, ALGX‐2460, ALGX‐2465 (30mg/kg) and ALGX‐2542 (10mg/kg) also inhibited mechanical allodynia in the SNL model with %MPE values of 38 to 65%. The effect of ALGX‐2542 (10mg/kg) was also evaluated in the paclitaxel chemotherapeutic‐induced neuropathic pain model and displayed similar efficacy in inhibiting mechanical hyperalgesia as observed in the SNL pain model. These results demonstrate Algomedix TRPA1 antagonists possess the requisite high potency, specificity, and pharmacokinetic properties to achieve substantial efficacy in multiple neuropathic pain models and hold promise as a new class of analgesic drugs for effectively and safely treating neuropathic pain patients. Support or Funding Information Supported by NIH grants 1R43DA031516 and 1R43AR065330 (JMH)

α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain

Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection

Resveratrol Attenuates Inflammatory Hyperalgesia by Inhibiting Glial Activation in Mice Spinal Cords

Inhibition of Schwann Cell Pannexin 1 Attenuates Neuropathic Pain Through the Suppression of Inflammatory Responses

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Effect of Spirocyclopiperazinium Salt Compound LXM-15 on Spinal Nerve Injury in Rats

Importance of N- and C-terminal residues of substance P 1-7 for alleviating allodynia in mice after peripheral administration

An Analgesic Peptide H-20 Attenuates Chronic Pain Via the PD-1 Pathway with Few Adverse Effects.

Effect and Underlying Mechanisms of Spirocyclopiperazinium Salt Compound DXL-A-24 in Rats Following Spinal Nerve Ligation.

Anti-Allodynic Effects of Polydeoxyribonucleotide in an Animal Model of Neuropathic Pain and Complex Regional Pain Syndrome

A Novel Class of Potent, Allosteric Trpa1 Antagonists Reverse Hyperalgesia in Multiple Rat Models of Neuropathic Pain

A Synthetic Peptide Disturbing GluN2A/SHP1 Interaction in Dorsal Root Ganglion Attenuated Pathological Pain

Inhibition of Endogenous NGF Degradation Induces Mechanical Allodynia and Thermal Hyperalgesia in Rats

Supraspinal Hyperalgesia and Spinal Analgesia by [Phe1ψ(ch2-Nh)gly2]nociceptin-(1–13)-nh2 in Rat

Chemogenetics Modulation of Electroacupuncture Analgesia in Mice Spared Nerve Injury-Induced Neuropathic Pain through TRPV1 Signaling Pathway

Disruption of SHP1/NMDA Receptor Signaling in Spinal Cord Dorsal Horn Alleviated Inflammatory Pain.

Heat Shock Protein 22 Attenuates Nerve Injury-induced Neuropathic Pain Via Improving Mitochondrial Biogenesis and Reducing Oxidative Stress Mediated By Spinal AMPK/PGC-1α Pathway in Male Rats

Substance P(1-7) induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain

Spexin/NPQ Induces FBJ Osteosarcoma Oncogene (fos) and Produces Antinociceptive Effect Against Inflammatory Pain in the Mouse Model